Clinical trial

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900

Drugs and interventions used in this trial

8 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

COMBINATION_PRODUCT · Unmapped registry intervention TTX-030, budigalimab and mFOLFOX6 Find medicine records · Find other trials using this name

COMBINATION_PRODUCT · Unmapped registry intervention TTX-030, budigalimab and docetaxel Find medicine records · Find other trials using this name

COMBINATION_PRODUCT · Unmapped registry intervention TTX-030 and mFOLFOX6 Find medicine records · Find other trials using this name

COMBINATION_PRODUCT · Unmapped registry intervention TTX-030 and budigalimab Find medicine records · Find other trials using this name

COMBINATION_PRODUCT · Unmapped registry intervention TTX-030, budigalimab, nab-paclitaxel and gemcitabine Find medicine records · Find other trials using this name

COMBINATION_PRODUCT · Unmapped registry intervention TTX-030 and pembrolizumab Find medicine records · Find other trials using this name

COMBINATION_PRODUCT · Unmapped registry intervention TTX-030, nab-paclitaxel and gemcitabine Find medicine records · Find other trials using this name

COMBINATION_PRODUCT · Unmapped registry intervention Budigalimab and mFOLFOX6 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-03-30

PhasePHASE1

Conditions

Solid Tumor, Adultunresolved

Interventions

TTX-030, budigalimab and mFOLFOX6COMBINATION_PRODUCT

TTX-030, budigalimab and docetaxelCOMBINATION_PRODUCT

TTX-030 and mFOLFOX6COMBINATION_PRODUCT

TTX-030 and budigalimabCOMBINATION_PRODUCT

TTX-030, budigalimab, nab-paclitaxel and gemcitabineCOMBINATION_PRODUCT

TTX-030 and pembrolizumabCOMBINATION_PRODUCT

TTX-030, nab-paclitaxel and gemcitabineCOMBINATION_PRODUCT

Budigalimab and mFOLFOX6COMBINATION_PRODUCT

Sponsors & collaborators

Trishula Therapeutics, Inc.lead sponsor

AbbViecollaborator

Mapped research locations

Los AngelesCalifornia, United States3 ChicagoIllinois, United States1 MiamiFlorida, United States1 San AntonioTexas, United States1 NashvilleTennessee, United States1 ClevelandOhio, United States1 PittsburghPennsylvania, United States1 OrlandoFlorida, United States1 OmahaNebraska, United States1 Salt Lake CityUtah, United States1 The BronxNew York, United States1 New OrleansLouisiana, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04306900 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.